Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

REstoration of SYNChronous Cardiac Function Due to Physiologic cArdiac Pacing Modalities With Clinical Endpoints (RESYNC-PACE)

8 juli 2026 bijgewerkt door: Peter Ezer, University of Pecs

REstoration of SYNChronous Cardiac Function Due to Physiologic cArdiac Pacing Modalities With Clinical Endpoints RESYNC-PACE

The goal of this observational study is to evaluate the long-term clinical outcomes of physiologic cardiac resynchronization therapy (CRT) using conduction system pacing strategies compared with conventional biventricular CRT in patients with heart failure with reduced ejection fraction (HFrEF) and electrical dyssynchrony.

The main questions it aims to answer are:

  • Does physiologic CRT (including left bundle branch area pacing [LBBAP] and LBBAP-optimized CRT) reduce the combined risk of all-cause mortality and heart failure hospitalization compared with conventional biventricular CRT?
  • Does physiologic CRT improve cardiac function and reverse ventricular remodeling more effectively than conventional CRT?

Participants receiving physiologic CRT as part of routine clinical care will undergo standard follow-up evaluations, including electrocardiography, echocardiography, laboratory testing, and device interrogation. Clinical outcomes will be collected prospectively for 24 months and compared with a historical cohort of patients treated with conventional biventricular CRT.

The study will assess clinical outcomes, echocardiographic response, electrical resynchronization parameters, and device-related safety in a real-world heart failure population.

Studie Overzicht

Gedetailleerde beschrijving

Background

Heart failure with reduced ejection fraction (HFrEF) is associated with substantial morbidity, mortality, and healthcare utilization despite continuous advances in guideline-directed medical therapy. Cardiac resynchronization therapy (CRT) has become an established treatment for patients with symptomatic HFrEF and electrical dyssynchrony. Conventional biventricular pacing improves ventricular synchrony and clinical outcomes; however, approximately one-third of treated patients do not achieve a satisfactory response.

Conduction system pacing (CSP), particularly left bundle branch area pacing (LBBAP), has emerged as a physiological pacing strategy capable of directly engaging the native His-Purkinje conduction system. Compared with conventional biventricular pacing, CSP may produce more physiological ventricular activation, narrower paced QRS complexes, improved electrical synchrony, and greater reverse ventricular remodeling. Nevertheless, evidence regarding its long-term effectiveness in routine clinical practice remains limited, particularly in heterogeneous populations with different conduction abnormalities.

Study Rationale

The RESYNC-PACE study was designed to evaluate the effectiveness of individualized physiologic cardiac resynchronization strategies in a real-world population of patients with HFrEF requiring CRT.

The study investigates two complementary physiologic CRT approaches according to the underlying conduction disturbance. In patients with typical left bundle branch block (LBBB), left ventricular lead implantation is guided by the qLV ratio to achieve optimal electrical resynchronization through individualized coronary sinus lead positioning. In patients with intraventricular conduction delay (IVCD), a conduction system pacing strategy is applied using left bundle branch area pacing. When conduction system pacing alone results in incomplete electrical correction, defined by a paced QRS duration greater than 130 ms, an additional coronary sinus left ventricular lead is implanted to establish Left Bundle Branch Area Pacing Optimized Cardiac Resynchronization Therapy (LOT-CRT).

This individualized treatment algorithm reflects contemporary physiological concepts of ventricular resynchronization rather than a single implantation strategy and represents the principal scientific concept investigated in the study.

Scientific Objectives

The study aims to determine whether physiologic CRT strategies provide superior long-term clinical outcomes compared with conventional biventricular CRT when implemented in routine clinical practice.

In addition to evaluating clinical outcomes, the study investigates the relationship between electrical resynchronization, ventricular reverse remodeling, myocardial scar characteristics assessed by cardiac magnetic resonance imaging, and long-term prognosis. Particular emphasis is placed on identifying imaging-, electrocardiographic-, and device-derived predictors of CRT response that may facilitate patient selection and optimization of resynchronization therapy.

Study Methodology

RESYNC-PACE is a single-center, ambispective observational cohort study performed at the University of Pécs Clinical Centre Heart Institute. Consecutive patients undergoing physiologic CRT constitute the prospective cohort, while a historical cohort of patients treated with conventional biventricular CRT serves as the comparator.

All therapeutic procedures are performed as part of routine clinical care using commercially available CE-marked cardiac implantable electronic devices according to their approved indications and current international guideline recommendations. The study does not introduce experimental devices or procedures beyond standard clinical practice but prospectively evaluates the clinical performance of an individualized physiological CRT algorithm.

The comprehensive study database integrates demographic, clinical, electrocardiographic, echocardiographic, cardiac magnetic resonance imaging, procedural, device-derived, and long-term follow-up data. This integrated approach enables detailed evaluation of the mechanisms underlying CRT response and supports the development of patient-specific resynchronization strategies.

Expected Clinical Significance

The RESYNC-PACE study is expected to generate real-world evidence regarding the effectiveness of conduction system pacing-guided CRT strategies and individualized resynchronization algorithms. The findings may improve patient selection, optimize implantation strategies for different conduction disorders, and contribute to the growing evidence supporting physiologic cardiac resynchronization therapy in patients with heart failure.

Studietype

Observationeel

Inschrijving (Geschat)

50

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Peter Ezer MD PhD, assistant professor
  • Telefoonnummer: +36305468840
  • E-mail: ezerpeti@gmail.com

Studie Locaties

    • Baranya
      • Pécs, Baranya, Hongarije, 7621
        • Heart Institute , University of Pécs

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

The study population consists of adult patients with heart failure with reduced ejection fraction (HFrEF) who are treated at the University of Pécs Clinical Centre Heart Institute and meet contemporary guideline indications for cardiac resynchronization therapy (CRT). Eligible participants have symptomatic heart failure despite guideline-directed medical therapy, left ventricular systolic dysfunction, and evidence of electrical dyssynchrony manifested by left bundle branch block (LBBB) or intraventricular conduction delay (IVCD). The prospective cohort includes patients undergoing conduction system pacing-based CRT as part of routine clinical care, while the historical control cohort includes patients previously treated with conventional biventricular CRT at the same institution. The study population represents a real-world heart failure population routinely referred for CRT implantation in tertiary cardiovascular care.

Beschrijving

Inclusion Criteria:

  • Age ≥18 years.
  • Symptomatic heart failure despite guideline-directed medical therapy.
  • Left ventricular ejection fraction (LVEF) ≤40%.
  • Indication for cardiac resynchronization therapy according to contemporary ESC guideline recommendations.
  • QRS duration ≥150 ms with either:

Left bundle branch block (LBBB), or Intraventricular conduction delay (IVCD).

  • Planned implantation of a CRT system
  • Ability to provide written informed consent
  • Expected survival greater than 24 months.

Exclusion Criteria:

  • Age <18 years and Age 100 < years
  • Pregnancy or breastfeeding.
  • Inability or unwillingness to provide informed consent.
  • Life expectancy <12 months due to non-cardiac comorbidities.
  • Active systemic infection or infection involving a cardiac implantable electronic device.
  • Reversible causes of heart failure expected to improve without CRT.
  • Participation in another interventional clinical trial that may affect study outcomes.
  • Inability to comply with follow-up requirements.
  • Missing essential baseline or follow-up data (retrospective cohort).
  • Any condition that, in the opinion of the investigators, would make participation inappropriate or interfere with study assessments.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Left bundle branch block patients

LBBB Cohort (qLV-guided Cardiac Resynchronization Therapy)

Patients in this cohort have symptomatic heart failure with reduced left ventricular ejection fraction and complete left bundle branch block (LBBB) according to contemporary guideline criteria. Cardiac resynchronization therapy is performed using a personalized implantation strategy guided by the qLV ratio, defined as the interval between QRS onset and local left ventricular activation divided by the intrinsic QRS duration. The left ventricular lead is positioned at the site with the longest achievable electrical delay to maximize resynchronization benefit. Patients receive either conventional biventricular CRT or LOT- CRT according to clinical decision-making and anatomical feasibility. The cohort is followed longitudinally to evaluate the relationship between qLV-guided lead placement, electrical resynchronization, reverse ventricular remodeling, heart failure hospitalization, and all-cause mortality.

Conduction System Pacing-Guided Cardiac Resynchronization Therapy is an individualized resynchronization strategy used in patients with heart failure, reduced left ventricular ejection fraction, and electrical dyssynchrony. The intervention is based on direct recruitment of the native cardiac conduction system through left bundle branch area pacing (LBBAP). During implantation, electrical resynchronization is assessed using electrocardiographic and device-derived parameters. In patients with intraventricular conduction delay or incomplete electrical correction, additional left ventricular pacing may be provided using a coronary sinus lead, resulting in Left Bundle Branch Area Pacing Optimized Cardiac Resynchronization Therapy (LOT-CRT). The intervention aims to achieve more physiological ventricular activation than conventional biventricular pacing, improve electrical synchrony, promote reverse ventricular remodeling, and reduce heart failure-related adverse events.
Andere namen:
  • Cardiac resynchronization therapy using left bundle branch area pacing with or without LV lead optimization.
  • Cardiac resynchronization guided by conduction system pacing to improve ventricular synchrony.
Intraventricular conduction delay patients

IVCD Cohort (Conduction System Pacing-Guided Resynchronization Strategy)

Patients in this cohort have symptomatic heart failure with reduced left ventricular ejection fraction and intraventricular conduction delay (IVCD) without typical left bundle branch block morphology. The resynchronization strategy is guided by the degree of electrical correction achieved with conduction system pacing. During implantation, left bundle branch area pacing (LBBAP) is attempted and paced QRS duration is assessed. If conduction system pacing alone results in a paced QRS duration greater than 130 ms, a Left Bundle Branch Area Pacing Optimized Cardiac Resynchronization Therapy (LOT-CRT) system is implanted by adding a left ventricular lead to further improve ventricular synchrony. The cohort is followed longitudinally to evaluate the association between electrical resynchronization, reverse ventricular remodeling, heart failure hospitalization, and all-cause mortality.

Conduction System Pacing-Guided Cardiac Resynchronization Therapy is an individualized resynchronization strategy used in patients with heart failure, reduced left ventricular ejection fraction, and electrical dyssynchrony. The intervention is based on direct recruitment of the native cardiac conduction system through left bundle branch area pacing (LBBAP). During implantation, electrical resynchronization is assessed using electrocardiographic and device-derived parameters. In patients with intraventricular conduction delay or incomplete electrical correction, additional left ventricular pacing may be provided using a coronary sinus lead, resulting in Left Bundle Branch Area Pacing Optimized Cardiac Resynchronization Therapy (LOT-CRT). The intervention aims to achieve more physiological ventricular activation than conventional biventricular pacing, improve electrical synchrony, promote reverse ventricular remodeling, and reduce heart failure-related adverse events.
Andere namen:
  • Cardiac resynchronization therapy using left bundle branch area pacing with or without LV lead optimization.
  • Cardiac resynchronization guided by conduction system pacing to improve ventricular synchrony.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Composite of All-Cause Mortality and Heart Failure Hospitalization
Tijdsspanne: 24 months
Time to first occurrence of the composite endpoint of all-cause mortality or hospitalization due to worsening heart failure during the 24-month follow-up period.
24 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Left Ventricular Ejection Fraction (LVEF)
Tijdsspanne: Baseline to 24 months

Change in left ventricular ejection fraction measured by transthoracic echocardiography between baseline and 24-month follow-up.

Ejection fraction is measured in percentage (%). Improvement in ejection fraction is detected as increase in percentage-value.

Baseline to 24 months
Change in Left Ventricular End-Systolic Volume ( LV ESV)
Tijdsspanne: Baseline to 24 months

Change in left ventricular end-systolic volumen measured by echocardiography between baseline and 24-month follow-up.

Left ventricular end-systolic volume in measured in mililiters ( ml) , decrease in LV ESV is a sign of clinical response on therapy.

Baseline to 24 months
Change in paced QRS Duration
Tijdsspanne: Baseline to 24 months

Reduction in QRS duration following cardiac resynchronization therapy compared with baseline electrocardiographic measurements.

Paced QRS duration is measured in miliseconds (ms). Decrease in paced QRS duration compared to preoperative QRS duration is marked as a good signal in cardiac resynchronization therapy.

Baseline to 24 months
New York Heart Association Heart Failure Functional Status
Tijdsspanne: Baseline to 24 months

Change in New York Heart Association (NYHA) functional class from baseline to follow-up. Stage I-IV.

NYHA improvement is detected as decrease in NYHA stage grade.

Baseline to 24 months

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Device-Related and Procedure-Related Complications
Tijdsspanne: 24 months
Incidence of device-related and procedure-related adverse events, including lead dislodgement, infection, pneumothorax, pocket hematoma, and system revision.
24 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

29 juni 2026

Primaire voltooiing (Geschat)

29 juni 2030

Studie voltooiing (Geschat)

29 juni 2031

Studieregistratiedata

Eerst ingediend

28 juni 2026

Eerst ingediend dat voldeed aan de QC-criteria

28 juni 2026

Eerst geplaatst (Werkelijk)

6 juli 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

10 juli 2026

Laatste update ingediend die voldeed aan QC-criteria

8 juli 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • FF107 RESYNC-PACE ver1.0
  • Biotronik Research Grant FF107 (Ander subsidie-/financieringsnummer: BIOTRONIK SE & Co. KG Woermannkehre 1 12359 Berlin)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Beschrijving IPD-plan

ndividual participant data will be shared only in a de-identified form and in accordance with applicable data protection regulations, institutional policies, and informed consent provisions. Data sharing may be limited where participant privacy, ethical considerations, or legal requirements prevent full disclosure of individual-level data.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren